Viking Therapeutics (VKTX) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

—

Revenue (quarter)

—

Revenue growth (year over year)

—

Gross profit (trailing twelve months)

—

Gross margin

—

Net income (trailing twelve months)

—

Net income (quarter)

−$128.0M

Net income growth (year over year)

−95.27%

Net margin

—

Return on equity

−88.85%

EPS (trailing twelve months)

−$4.67

Book value per share

$3.50

P/E (trailing twelve months)

—

Price to book

8.08

Debt to assets

21.76%

Payout ratio

—

Dividend yield

—

Company profile

Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.

• How do I buy stock in Viking Therapeutics (VKTX)?

  VKTX trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.